GlaxoSmithKline’s China bribery case

A senior pharmaceutical executive in China ended up at the center of a bribery investigation that went far beyond an ordinary corporate misconduct case. Mark Reilly, the British former head of GlaxoSmithKline's operations in China, pleaded guilty to bribery related charges and was eventually deported to the United Kingdom after receiving a three year suspended prison sentence.

Before that happened, Reilly had reportedly been prevented from leaving China for an entire year. Investigators accused him of overseeing what was described in contemporary reporting as a "criminal godfather" scheme designed to encourage doctors to prescribe GlaxoSmithKline drugs. The allegations involved enormous sums, reportedly around £300 million, along with cash payments and sexual inducements.

The case became particularly notable because of who was involved. This wasn't an isolated sales employee or an anonymous intermediary, but a senior executive at one of the world's largest pharmaceutical companies. His guilty plea, the travel restrictions, suspended sentence and eventual deportation turned the investigation into a major international example of how aggressively authorities could pursue alleged corruption within the pharmaceutical industry.